The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study - PubMed (original) (raw)

Clinical Trial

doi: 10.1016/j.pupt.2007.07.002. Epub 2007 Jul 17.

Supria Singh, Rami El-Wali, Michael Flashner, Amie E Franklin, William J Garner, Burton F Dickey, Sergio Parra, Stephen Ruoss, Felix Shardonofsky, Brian J O'Connor, Clive Page, Richard A Bond

Affiliations

Clinical Trial

The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study

Nicola A Hanania et al. Pulm Pharmacol Ther. 2008.

Abstract

Beta-blockers are currently contraindicated in asthma because their acute administration may be associated with worsening bronchospasm. However, their effects and safety with their chronic administration are not well evaluated. The rationale for this pilot study was based on the paradigm shift that was observed with the use of beta-blockers in congestive heart failure, which once contraindicated because of their acute detrimental effects, have now been shown to reduce mortality with their chronic use. We hypothesized that certain beta-blockers may also be safe and useful in chronic asthma therapy. In this prospective, open-label, pilot study, we evaluated the safety and effects of escalating doses of the beta-blocker, nadolol, administered over 9 weeks to 10 subjects with mild asthma. Dose escalation was performed on a weekly basis based on pre-determined safety, lung function, asthma control and hemodynamic parameters. The primary objective was to evaluate safety and secondary objectives were to evaluate effects on airway hyperresponsiveness, and indices of respiratory function. The escalating administration of nadolol was well tolerated. In 8 out of the 10 subjects, 9 weeks of nadolol treatment produced a significant, dose-dependent increase in PC20 that reached 2.1 doubling doses at 40 mg (P<0.0042). However, there was also a dose-independent 5% reduction in mean FEV1 over the study period (P<0.01). We conclude that in most patients with mild asthma, the dose-escalating administration of the beta-blocker, nadolol, is well tolerated and may have beneficial effects on airway hyperresponsiveness. Our findings warrant further testing in future larger trials.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Schematic description of study protocol

V = Visit, ACQ= Asthma Control Questionnaire Score, PEFR = peak expiratory flow rates, PC20: provocative concentration of methacholine producing a 20% fall in FEV1, HR = heart rate, BP = Blood pressure.

Figure 2A & 2B

Figure 2A & 2B. The effect of chronic treatment with nadolol on the PC20 methacholine in mild asthmatic patients

A. Data shown as pre- and post-treatment with final nadolol doses of 10, 20, and 40 mg. Mean values ± SEM are also shown. Comparisons between pre- and post-treatment with nadolol were done using paired t-test. *P<0.05. B. Data for each patient shown as the doubling dose in PC20 methacholine values between baseline and after treatment relative to final doses of nadolol of 10, 20, and 40 mg. Mean values ± SEM are also shown.

Figure 3

Figure 3. Correlation Between Nadolol Dose and Change in PC20

Correlation between nadolol dose log (mg/Kg) versus the percentage of change in PC20 as compared with baseline levels for each patient. Least squares linear regression correlation: r = 0.86; p=0.0016

Similar articles

Cited by

References

    1. Lipworth BJ. Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern? Drug Saf. 1997;16:295–308. - PubMed
    1. Shore SA, Drazen JM. Beta-agonists and asthma: too much of a good thing? J Clin Invest. 2003;112:495–497. - PMC - PubMed
    1. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144:904–912. - PubMed
    1. Abramson MJ, Walters J, Walters EH. Adverse effects of beta-agonists: are they clinically relevant? Am J Respir Med. 2003;2:287–297. - PubMed
    1. Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet. 1993;342:833–837. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources